001     306176
005     20251203110707.0
024 7 _ |a 10.1016/j.breast.2025.104619
|2 doi
024 7 _ |a pmid:41223770
|2 pmid
024 7 _ |a 0960-9776
|2 ISSN
024 7 _ |a 1532-3080
|2 ISSN
037 _ _ |a DKFZ-2025-02416
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Billaud, Amandine
|b 0
245 _ _ |a Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764756401_1331673
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The breast cancer risk conferred by germline protein truncating variants (PTVs) in known and putative breast cancer genes has been extensively investigated. However, the effect of FANCM PTVs on breast cancer risk remains unclear. Our previous clinical, genetic and functional results on the N-terminal p.Arg658∗ and the two C-terminal p.Gln1701∗ and p.Gly1906Alafs∗12 variants suggested that FANCM PTVs may confer different risks for ER-negative (ER-neg) and triple-negative (TN) breast cancer subtypes. Here, we performed meta-analyses of seven studies totaling 144 681 breast cancer cases and 123 632 controls. FANCM PTVs were tested for association with breast cancer risk overall and the disease clinical subtypes by single variant and burden analyses. Two CRISPR-Cas9-based functional assays were also conducted to test the fitness of cells after knock-in of the p.Arg658∗, p.Gln1701∗ and p.Gly1906Alafs∗12 PTVs and the sensitivity of different FANCM regions to genome editing. Our results suggest that the N-terminal FANCM region upstream of p.Tyr725 harbors essential functions, whereas downstream regions appear dispensable. This is supported by our genetic data which indicate that all FANCM PTVs, excluding the two C-terminal p.Gln1701∗ and p.Gly1906Alafs∗12, are associated with an increased risk of ER-neg (OR = 1.41, P = 0.023) and TN (OR = 1.64, P = 0.0023). Notably, PTVs upstream of AA position 670 are associated with a moderate risk of developing TN breast cancer, and that even when the p.Arg658∗ carriers were excluded from the analysis. Importantly, our results confirm previous data indicating that p.Arg658∗ carriers are at moderate risk of developing ER-neg (OR = 2.08, P = 0.030) and TN (OR = 3.26; P = 0.0034), whereas carriers of p.Gln1701∗ and p.Gly1906Alafs∗12 should not be considered at increased risk. Our data are useful for counseling carriers of FANCM PTVs, but further analyses are warranted to obtain more precise risk estimates.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Breast cancer risk
|2 Other
650 _ 7 |a CRISPR-Cas9
|2 Other
650 _ 7 |a FANCM
|2 Other
650 _ 7 |a Gene editing
|2 Other
650 _ 7 |a Genetic predisposition
|2 Other
650 _ 7 |a Meta-analysis
|2 Other
700 1 _ |a Figlioli, Gisella
|b 1
700 1 _ |a Mooser, Clémence
|b 2
700 1 _ |a Casamassima, Irene
|b 3
700 1 _ |a Azzoni, Violette
|b 4
700 1 _ |a Srivatsa, Jahnavi
|b 5
700 1 _ |a Colombo, Mara
|b 6
700 1 _ |a Caleca, Laura
|b 7
700 1 _ |a Ahearn, Thomas U
|b 8
700 1 _ |a Andrulis, Irene L
|b 9
700 1 _ |a Antoniou, Antonis C
|b 10
700 1 _ |a Beckmann, Matthias W
|b 11
700 1 _ |a Behrens, Sabine
|0 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
|b 12
|u dkfz
700 1 _ |a Bermisheva, Marina
|b 13
700 1 _ |a Bogdanova, Natalia V
|b 14
700 1 _ |a Bolla, Manjeet K
|b 15
700 1 _ |a Bonanni, Bernardo
|b 16
700 1 _ |a Brüning, Thomas
|b 17
700 1 _ |a Camp, Nicola J
|b 18
700 1 _ |a Campbell, Archie
|b 19
700 1 _ |a Castelao, Jose E
|b 20
700 1 _ |a Cessna, Melissa H
|b 21
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 22
700 1 _ |a NBCS Collaborators
|b 23
|e Collaboration Author
700 1 _ |a Czene, Kamila
|b 24
700 1 _ |a Dennis, Joe
|b 25
700 1 _ |a Devilee, Peter
|b 26
700 1 _ |a Dörk, Thilo
|b 27
700 1 _ |a Dunning, Alison M
|b 28
700 1 _ |a Eriksson, Mikael
|b 29
700 1 _ |a Evans, D Gareth
|b 30
700 1 _ |a Fasching, Peter A
|b 31
700 1 _ |a Figueroa, Jonine D
|b 32
700 1 _ |a Gabrielson, Marike
|b 33
700 1 _ |a Gago-Dominguez, Manuela
|b 34
700 1 _ |a González-Neira, Anna
|b 35
700 1 _ |a Guénel, Pascal
|b 36
700 1 _ |a Hadjisavvas, Andreas
|b 37
700 1 _ |a Hahnen, Eric
|b 38
700 1 _ |a Hamann, Ute
|0 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
|b 39
700 1 _ |a Hillemanns, Peter
|b 40
700 1 _ |a Hollestelle, Antoinette
|b 41
700 1 _ |a Hooning, Maartje J
|b 42
700 1 _ |a Hoppe, Reiner
|b 43
700 1 _ |a Howell, Anthony
|b 44
700 1 _ |a Investigators, kConFab
|b 45
|e Collaboration Author
700 1 _ |a Jakubowska, Anna
|b 46
700 1 _ |a Kristensen, Vessela N
|b 47
700 1 _ |a Lubiński, Jan
|b 48
700 1 _ |a Lush, Michael
|b 49
700 1 _ |a Manoukian, Siranoush
|b 50
700 1 _ |a Mavroudis, Dimitrios
|b 51
700 1 _ |a Milne, Roger L
|b 52
700 1 _ |a Mulligan, Anna Marie
|b 53
700 1 _ |a Newman, William G
|b 54
700 1 _ |a Obi, Nadia
|b 55
700 1 _ |a Panayiotidis, Mihalis I
|b 56
700 1 _ |a Pita, Guillermo
|b 57
700 1 _ |a Rashid, Muhammad U
|0 P:(DE-HGF)0
|b 58
700 1 _ |a Rhenius, Valerie
|b 59
700 1 _ |a Saloustros, Emmanouil
|b 60
700 1 _ |a Sawyer, Elinor J
|b 61
700 1 _ |a Schmutzler, Rita K
|b 62
700 1 _ |a Shah, Mitul
|b 63
700 1 _ |a Southey, Melissa C
|b 64
700 1 _ |a Spurdle, Amanda B
|b 65
700 1 _ |a Tomlinson, Ian
|b 66
700 1 _ |a Truong, Thérèse
|b 67
700 1 _ |a Wang, Qin
|b 68
700 1 _ |a Wendt, Camilla
|b 69
700 1 _ |a Auer, Paul L
|b 70
700 1 _ |a Boddicker, Nicholas J
|b 71
700 1 _ |a Bodelon, Clara
|b 72
700 1 _ |a Burnside, Elizabeth S
|b 73
700 1 _ |a Chen, Fei
|b 74
700 1 _ |a Couch, Fergus J
|b 75
700 1 _ |a Domchek, Susan M
|b 76
700 1 _ |a Eliassen, Heather A
|b 77
700 1 _ |a Haiman, Christopher
|b 78
700 1 _ |a Hodge, James M
|b 79
700 1 _ |a Hu, Chunling
|b 80
700 1 _ |a Huang, Hongyan
|b 81
700 1 _ |a Lindstrom, Sara
|b 82
700 1 _ |a Martinez, Maria Elena
|b 83
700 1 _ |a Nathanson, Katherine L
|b 84
700 1 _ |a Neuhausen, Susan L
|b 85
700 1 _ |a O'Brien, Katie M
|b 86
700 1 _ |a Olson, Janet E
|b 87
700 1 _ |a Palmer, Julie R
|b 88
700 1 _ |a Patel, Alpa V
|b 89
700 1 _ |a Ruddy, Kathryn J
|b 90
700 1 _ |a Sandler, Dale P
|b 91
700 1 _ |a Teras, Lauren R
|b 92
700 1 _ |a Weinberg, Clarice R
|b 93
700 1 _ |a Weitzel, Jeffrey N
|b 94
700 1 _ |a Winham, Stacey J
|b 95
700 1 _ |a Yadav, Siddhartha
|b 96
700 1 _ |a Yao, Song
|b 97
700 1 _ |a Zirpoli, Gary
|b 98
700 1 _ |a Janatova, Marketa
|b 99
700 1 _ |a Kleibl, Zdenek
|b 100
700 1 _ |a Kleiblova, Petra
|b 101
700 1 _ |a Soukupova, Jana
|b 102
700 1 _ |a consortium, CZECANCA
|b 103
|e Collaboration Author
700 1 _ |a Zhao, Qihong
|b 104
700 1 _ |a Devereux, Lisa
|b 105
700 1 _ |a James, Paul A
|b 106
700 1 _ |a Campbell, Ian G
|b 107
700 1 _ |a Nguyen-Dumont, Tu
|b 108
700 1 _ |a Dowty, James G
|b 109
700 1 _ |a Andrieu, Nadine
|b 110
700 1 _ |a Lesueur, Fabienne
|b 111
700 1 _ |a Stoppa-Lyonnet, Dominique
|b 112
700 1 _ |a GENESIS
|b 113
|e Collaboration Author
700 1 _ |a Hoya, Miguel de la
|b 114
700 1 _ |a Radice, Paolo
|b 115
700 1 _ |a Sørensen, Claus Storgaard
|b 116
700 1 _ |a Peterlongo, Paolo
|b 117
773 _ _ |a 10.1016/j.breast.2025.104619
|g Vol. 85, p. 104619 -
|0 PERI:(DE-600)2009043-2
|p 104619
|t The breast
|v 85
|y 2025
|x 0960-9776
909 C O |p VDB
|o oai:inrepo02.dkfz.de:306176
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 39
|6 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 58
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T14:49:13Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T14:49:13Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T14:49:13Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BREAST : 2022
|d 2024-12-19
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-19
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-19
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-19
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)B072-20160331
|k B072
|l Molekulargenetik des Mammakarzinoms
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)B072-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21